| Spinal Muscular Atrophy
Evrysdi vs Zolgensma
Side-by-side clinical, coverage, and cost comparison for spinal muscular atrophy.Deep comparison between: Evrysdi vs Zolgensma with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZolgensma has a higher rate of injection site reactions vs Evrysdi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zolgensma but not Evrysdi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Evrysdi
Zolgensma
At A Glance
Oral
Daily
SMN2 splicing modifier
IV infusion
Single dose
AAV9-based gene therapy
Indications
- Spinal Muscular Atrophy
- Spinal Muscular Atrophy
Dosing
Spinal Muscular Atrophy Once daily orally with or without food: <2 months 0.15 mg/kg; 2 months to <2 years 0.2 mg/kg; >=2 years weighing <20 kg 0.25 mg/kg; >=2 years weighing >=20 kg 5 mg (oral solution or tablet).
Spinal Muscular Atrophy Single IV infusion of 1.1 x 10^14 vg/kg body weight administered over 60 minutes; systemic corticosteroids (oral prednisolone 1 mg/kg/day) initiated one day prior to infusion and continued for 30 days, then tapered over 28 days or longer if liver function abnormalities persist.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) - Later-onset SMA fever, diarrhea, rash
Most common (>=10%) - Infantile-onset SMA fever, diarrhea, rash, upper respiratory tract infection, lower respiratory tract infection, constipation, vomiting, cough
Most common (>=5%) elevated aminotransferases, vomiting
Postmarketing thrombotic microangiopathy, thrombocytopenia, acute liver failure, acute liver injury, pyrexia, infusion-related reactions, troponin increased
Pharmacology
Risdiplam is an SMN2 splicing modifier that increases exon 7 inclusion in SMN2 mRNA transcripts, resulting in increased production of full-length SMN protein in the brain to treat spinal muscular atrophy caused by chromosome 5q mutations leading to SMN protein deficiency.
Onasemnogene abeparvovec is a recombinant AAV9-based gene therapy designed to deliver a functional copy of the SMN1 gene, restoring SMN protein expression that is deficient in spinal muscular atrophy due to bi-allelic mutations in the SMN1 gene; intravenous administration results in cell transduction and expression of the SMN protein.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Evrysdi
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Zolgensma
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Evrysdi
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (5/8)
Zolgensma
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Evrysdi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Zolgensma
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Evrysdi Co-pay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: Spinal Muscular Atrophy
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EvrysdiView full Evrysdi profile
ZolgensmaView full Zolgensma profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.